CeriBell

CeriBell makes a headband that checks brain activity for seizures. It helps doctors find brain emergencies in sick hospital patients. The system uses smart software to alert nurses to hidden seizures.

The Modern Brain Care Kit

• Wearables: Single-use headbands and headcaps used for electroencephalography (EEG), which is a test that measures electrical brain activity; accommodates both adult and infant patients.
• Recorder: Battery-operated, pocket-sized device that captures and stores brain activity data; transmits signals wirelessly to a cloud platform for remote review.
• Clarity AI: Software algorithm using artificial intelligence (AI) to identify hidden seizures in real-time; displays results as a seizure burden score to help bedside clinicians make decisions.
• Cloud Portal: Web-based platform for doctors to review brain wave recordings remotely; provides data on any web-enabled device to speed up diagnosis.

New Markets and FDA Clearances

• Obtained **FDA** (Food and Drug Administration) clearance in December 2025 for a tool to monitor delirium, a state of sudden confusion common in intensive care patients.
• Received Breakthrough Device Designation in January 2026 for a new system to detect Large Vessel Occlusion (LVO) strokes, which are major blockages in brain blood vessels.
• Gained **CMS** (Centers for Medicare and Medicaid Services) approval for a New Technology Add-on Payment (NTAP) to help hospitals cover costs for the Clarity software.
• Secured High authorization from **FedRAMP** (Federal Risk and Authorization Management Program) in April 2025 to offer products to Veterans Administration hospitals.
• Licensed key brain monitoring technology through an exclusive agreement with **Stanford University** to develop the current system.

What Makes the Technology Stand Out?

The system allows any trained healthcare professional to start a brain scan in five minutes without waiting for specialized technicians. This proprietary technology uses artificial intelligence to continuously monitor for non-convulsive seizures that lack physical symptoms.

Financial Performance Highlights

• Revenue reached $89.1 million for the fiscal year ended December 31, 2025, up 36% from 2024.
• Gross margin reached 88% for the fiscal year ended December 31, 2025, compared to 87% in the previous year.
• Net loss reached $13.5 million in Q4 2025, worsened 7.6% year-over-year.
• Free cash flow reached -$11 million in Q4 2025, worsened 6% year-over-year.

Bottom Line

CeriBell has transitioned from a specialized seizure tool to a broader brain monitoring platform for hospitals. Its integration of portable hardware and artificial intelligence addresses long-standing delays in neurological care for critically ill patients.